Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $15.0 million.

  • Tarsus Pharmaceuticals' Interest & Investment Income fell 0.15% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 7.66%. This contributed to the annual value of $15.0 million for FY2024, which is 45.25% up from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' Interest & Investment Income is $15.0 million, which was up 45.25% from $10.3 million recorded in FY2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Interest & Investment Income peaked at $15.0 million during FY2024, and registered a low of $36,000 during FY2021.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Interest & Investment Income value was $10.3 million (recorded in 2023), while the average stood at $9.6 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Interest & Investment Income crashed by 80.85% in 2021 and then soared by 9,619.44% in 2022.
  • Tarsus Pharmaceuticals' Interest & Investment Income (Yearly) stood at $188,000 in 2020, then plummeted by 80.85% to $36,000 in 2021, then surged by 9,619.44% to $3.5 million in 2022, then surged by 195.43% to $10.3 million in 2023, then skyrocketed by 45.25% to $15.0 million in 2024.